The American College of Rheumatology is urging CMS to reconsider its current policy of allowing insurers to exclude copay assistance programs from counting toward a patient’s deductible, according to a press release.
In a submitted comment to CMS Administrator Chiquita Brooks-LaSure, ACR President Douglas White, MD, PhD, stated that patients with rheumatic diseases often rely on higher-priced therapies, such as biologics, to manage their disease and improve their quality of life. He argued that copay assistance programs enable patient access to these necessary treatments.
“To allow